Topic Highlight
Copyright ©The Author(s) 2015.
World J Hepatol. Dec 8, 2015; 7(28): 2792-2810
Published online Dec 8, 2015. doi: 10.4254/wjh.v7.i28.2792
Figure 2
Figure 2 Sustained virologic response to 48 wk of combination therapy in patients with hepatitis C virus genotype-4 using standard-dose pegylated-interferon and ribavirin (pegylated-interferon-α2a 180 μg or pegylated-interferon-α2b 1. 5 mg/kg and RBV 1-1.2 g/d). All studies were randomized control trials with intention-to-treat analysis: (P < 0.001) (P < 0.01) (P = not supplied) (P = 0.43)[128-131]. PEG-IFN: Pegylated-interferon; RBV: Ribavirin.